Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I brentuximab vedotin in pediatric recurrent/refractory CD30-positive HL or systemic ALCL
jRCT1091220229Phase 1Completed
- Sponsor
- National Hospital Organization Nagoya Medical Center
- Start
- Nov 2015
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of brentuximab vedotin in Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), sponsored by National Hospital Organization Nagoya Medical Center. Primary endpoints: Dose-limiting toxicity (DLT) and Adverse events. Started Nov 2015; status: completed.
02
Drugs
brentuximab vedotin
03
Conditions
Hodgkin lymphoma (HL)anaplastic large cell lymphoma (ALCL)
Beyond the preview
Go deeper on jRCT1091220229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1091220229.